Cardiometabolic risk synthesis
Multi-domain stratification across cardiorespiratory fitness, body-composition trajectory, visceral adiposity, and muscle reserve — surfaced as explainable indices your clinicians can defend.
MPS turns physiologic testing data and clinical context into structured, defensible decision-support — configured to fit your institution’s protocols, reporting standards, and clinician workflows. Patent pending.
Multi-domain stratification across cardiorespiratory fitness, body-composition trajectory, visceral adiposity, and muscle reserve — surfaced as explainable indices your clinicians can defend.
VO₂max, VAT, ALMI, and grip strength — normalized into a clinical narrative with domain-level flags and trend-aware context that goes beyond isolated device readouts.
Designed for executive health, preventive cardiology, and longevity medicine — where the work is multi-axis interpretation and pre-emptive risk reduction over decades, not point-in-time diagnosis.
One consistent, institution-branded report format for every patient encounter — Healthspan Index, Biological Fitness Age, Sarcopenia Risk Score, longitudinal trajectory, and clinician-ready recommendations, all in one clinical document.
Measurement tiers, score thresholds, domain definitions, intervention pathways, and report templates are configured to fit your institutional protocols and reviewed by your clinical leadership before go-live.
HL7v2, FHIR, and SFTP/SDM ingestion patterns; report delivery via your EHR’s media-tab, results inbox, or downstream clinical document workflow. Built for clinical IT, not consumer wellness rails.
Illustrative operational impacts based on internal modeling and reference deployments. Actual results depend on patient population, panel composition, clinical pathway design, and institutional protocols.
MPS is positioned, languaged, and reported as a clinical decision-support layer. It fits cleanly into executive health, preventive cardiology, and longevity medicine service lines — and into the credibility standards that those service lines are held to.
Ingest the physiologic measurements and EHR context you already collect; deliver the report into the channel your clinicians already use; align thresholds to the protocols your clinical leadership already trusts. No parallel workflow.
Risk thresholds, phenotype definitions, and recommendation logic are documented and version-controlled — reviewable by your clinical leadership and your data/security teams during diligence and at each release.
MPS is licensed at the institutional level — health systems, longevity platforms, executive health programs, and clinical innovation groups. Commercial terms are structured for system-wide deployment, not individual practitioners.
Apogee has evaluated MPS-style composite outputs against NHANES-derived cohort data to test whether VO₂max, DEXA-derived body composition, VAT, ALMI, and grip-strength domains support clinically meaningful stratification beyond age and sex.
Arterial stiffness and CCTA-derived plaque metrics are planned 2027 clinical vertical extensions. They are not presented as current included metrics in the clinical MPS outputs.
Briefings cover platform scope, integration model, configuration approach, security and data review, pilot structure, and commercial terms — tuned to your service line.